Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Up 6.31%
As of Friday, November 06, Damora Therapeutics, Inc.’s DMRA share price has surged by 6.31%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Tudor Pop
Rosalio Madrigal
Rosalio Madrigal
Jenna Brashear
| Share Statistics | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,337.1 | $211.8 | 49% |
|
| Shares Out (Mil) | 61.8 | 55.4 | 52% |
|
| Institutional Ownership | 99.7% | 93.0% | 92% |
|
| Float (Mil) | 41.6 | 41.5 | 43% |
|
| Beta | 1.51 | 0.99 | 82% |
|
| Avg Daily Volume (000s) | 557 | 553 | 58% |
|
| Price Change (52-week) |
(8.5%) | 42.8% | 43% |
|
| Growth | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (43.2%) | (10.3%) | 9% |
|
| EPS (5yr) | 4.2% | 15.8% | 37 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (26.5%) | (15.7%) | 24% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.470) | ($1.885) | ($2.185) | |
| Month Ago EPS | ($0.473) | ($1.895) | ($2.173) | |
| # Rev Up | 0 | 2 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.470) | ($1.893) | ($2.143) | |
| Year/Year Chg | 17.5% | (98.8%) | (98.3%) | |
| Financials | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $41 | na |
|
| Net Income (TTM) (Mil) | ($292) | ($44) | 4% |
|
| EPS (TTM) | ($6.640) | ($1.500) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($59) | ($35) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 16% |
|
| Enterprise Value (Q1) (Mil) | $1,070 | $147 | 42% |
|
| Valuation | DMRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.65 | 2.01 | 73% |
|
| P/E | na | 17.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.6%) | na |
|
| ROA | (107.4%) | (47.4%) | 5% |
|
| ROE | (156.6%) | (53.1%) | 6% |
|
| Liabilities to Assets | 6.9% | 29.7% | 4% |
|
| F-Score | 2 | 3 | 7% |
|
Damora Therapeutics, Inc. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors